Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12584138 | Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies | 🖼🧊📄§ | 2026-03-24 | 2041-08-26 | 0 | 31 |
| 12584131 | Methods of gene therapy | 🖼🧊📄§ | 2026-03-24 | 2039-04-30 | 0 | 31 |
| 12584110 | Functional feline pancreatic cells from adipose tissue | 🖼🧊📄§ | 2026-03-24 | 2043-09-22 | 0 | 31 |
| 12584118 | Cas9 variants and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2042-09-30 | 0 | 31 |
| 12583902 | DNA-binding domain transactivators and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2040-02-24 | 0 | 31 |
| 12583898 | Therapeutic interferon alpha 1 proteins | 🖼🧊📄§ | 2026-03-24 | 2042-07-21 | 0 | 31 |
| 12583903 | Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof | 🖼🧊📄§ | 2026-03-24 | 2042-06-03 | 0 | 31 |
| 12583910 | T cell antigen receptor, multimeric complex thereof, and preparation method therefor and use thereof | 🖼🧊📄§ | 2026-03-24 | 2041-04-23 | 0 | 31 |
| 12583905 | Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells | 🖼🧊📄§ | 2026-03-24 | 2044-11-20 | 0 | 31 |
| 12583908 | Albumin protein variants, production thereof and uses of same | 🖼🧊📄§ | 2026-03-24 | 2045-01-16 | 0 | 31 |
| 12583916 | Methods to improve glucose tolerance in a subject by administering an antibody that binds to extracellular human metallothionein 1A (MT1A) | 🖼🧊📄§ | 2026-03-24 | 2043-07-24 | 0 | 31 |
| 12583914 | Methods of treating allergy using anti-bet v 1 antibodies | 🖼🧊📄§ | 2026-03-24 | 2043-12-19 | 0 | 31 |
| 12583920 | Compositions and methods for treatment and prevention of Alzheimer's disease | 🖼🧊📄§ | 2026-03-24 | 2042-04-03 | 0 | 31 |
| 12583922 | Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof | 🖼🧊📄§ | 2026-03-24 | 2042-03-22 | 0 | 31 |
| 12583927 | Anti-variable MUC1* antibodies and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2041-07-12 | 0 | 31 |
| 12583928 | Antibodies against IGFR-like receptor and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2042-02-24 | 0 | 31 |
| 12583934 | Anti-CD26 antibodies and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2042-09-16 | 0 | 31 |
| 12583931 | Antibody and chimeric antigen receptor (CAR) binding to CD70, and application thereof | 🖼🧊📄§ | 2026-03-24 | 2041-10-12 | 0 | 31 |
| 12583932 | CD38 and ICAM1 antibodies and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2039-11-15 | 0 | 31 |
| 12583941 | Fibroblast activation protein binding agents and use thereof | 🖼🧊📄§ | 2026-03-24 | 2040-03-27 | 0 | 31 |
| 12583938 | Protein biomarker and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2043-11-08 | 0 | 31 |
| 12583945 | Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof | 🖼🧊📄§ | 2026-03-24 | 2043-11-17 | 0 | 31 |
| 12584101 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | 🖼🧊📄§ | 2026-03-24 | 2043-09-22 | 0 | 31 |
| 12576143 | Teleost invariant chain cancer vaccine | 🖼🧊📄§ | 2026-03-17 | 2039-10-18 | 0 | 31 |
| 12577285 | Process for producing a composition of engineered T cells | 🖼🧊📄§ | 2026-03-17 | 2038-12-07 | 0 | 31 |
| 12577255 | MDM2-based modulators of proteolysis and associated methods of use | 🖼🧊📄§ | 2026-03-17 | 2042-01-06 | 0 | 31 |
| 12577312 | Methods for the treatment of melanoma using compositions of denosumab and PD-1 inhibitor | 🖼🧊📄§ | 2026-03-17 | 2045-02-26 | 0 | 31 |
| 12580049 | Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies | 🖼🧊📄§ | 2026-03-17 | 2042-12-23 | 0 | 31 |
| 12576119 | Bacteriophage compositions and methods for treatment of bacterial infections | 🖼🧊📄§ | 2026-03-17 | 2045-04-14 | 0 | 31 |
| 12576138 | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | 🖼🧊📄§ | 2026-03-17 | 2039-05-17 | 0 | 31 |
| 12577283 | Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products | 🖼🧊📄§ | 2026-03-17 | 2042-01-28 | 0 | 31 |
| 12577325 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-11-22 | 0 | 31 |
| 12577222 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-01-19 | 0 | 31 |
| 12576129 | Anthelmintic compositions and methods | 🖼🧊📄§ | 2026-03-17 | 2042-09-23 | 0 | 31 |
| 12576057 | Antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as active ingredient | 🖼🧊📄§ | 2026-03-17 | 2042-11-18 | 0 | 31 |
| 12576149 | Gamma delta T cells derived from induced pluripotent stem cells, and production method therefor | 🖼🧊📄§ | 2026-03-17 | 2045-01-14 | 0 | 31 |
| 12576053 | Use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl) methylidenejinden-1-yl] acetic acid | 🖼🧊📄§ | 2026-03-17 | 2038-04-11 | 0 | 31 |
| 12576123 | Epitope-based approach for allergy treatments and inhibitors for Crohn's disease | 🖼🧊📄§ | 2026-03-17 | 2040-03-13 | 0 | 31 |
| 12576154 | Conjugates of PSMA-binding moieties with cytotoxic agents | 🖼🧊📄§ | 2026-03-17 | 2043-07-31 | 0 | 31 |
| 12576062 | Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the MCTs | 🖼🧊📄§ | 2026-03-17 | 2040-03-17 | 0 | 31 |
| 12576118 | Bacteriophages for the treatment of tuberculosis | 🖼🧊📄§ | 2026-03-17 | 2040-05-21 | 0 | 31 |
| 12576045 | Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia | 🖼🧊📄§ | 2026-03-17 | 2043-02-06 | 0 | 31 |
| 12576166 | Contrast agents for detection of enzyme activities based on melanin synthesis | 🖼🧊📄§ | 2026-03-17 | 2041-07-26 | 0 | 31 |
| 12576158 | Antibody drug conjugates with cleavable linkers | 🖼🧊📄§ | 2026-03-17 | 2040-05-22 | 0 | 31 |
| 12576040 | Ionizable lipids and methods of manufacture and use thereof | 🖼🧊📄§ | 2026-03-17 | 2041-10-13 | 0 | 31 |
| 12576140 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | 🖼🧊📄§ | 2026-03-17 | 2041-07-29 | 0 | 31 |
| 12576133 | Antigen-binding agents that specifically bind epidermal growth factor receptor variant III | 🖼🧊📄§ | 2026-03-17 | 2040-03-23 | 0 | 31 |
| 12576083 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | 🖼🧊📄§ | 2026-03-17 | 2044-01-17 | 0 | 31 |
| 12576094 | Combination cannabinoid-phenylethanoid formulation for treatment of inflammation and methods related thereto | 🖼🧊📄§ | 2026-03-17 | 2040-11-20 | 0 | 31 |
| 12576077 | Composition for preventing, alleviating or treating cancer | 🖼🧊📄§ | 2026-03-17 | 2043-08-28 | 0 | 31 |